Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.